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Objective: Long-term survival is rare in patients with glioblastoma (GBM). We set out to determine prognostic
factors for patients with favorable and poor prognosis in regard of tumor localization to the subventricular zone
(SZV).
Methods: We reviewed the clinical records, pre-operative and post-operative MRI imaging of 50 LTS long-term
survivors (LTS) (> 3 years) and 50 short-term survivors (STS) (< 1 year) with glioblastoma. These groups were
matched for clinical characteristics being consistently associated with prolonged or shortened survival. All patients
had undergone initial surgery or biopsy to confirm GBM diagnosis followed by radio- or chemoradiotherapy.
Results: LTS had a median progression-free survival PFS of 25, 4 months (2, 3–97, 8 months) and overall-survival
(OS) of 55, 9 months (38, 2-98, 6 months) compared to STS who had a significantly lower PFS of 4, 2 months
(1, 4–10, 2 months) and OS of 6, 6 months (2, 2–11, 6 months) (each p < 0,001).
Survival analysis showed that age under 60 years (p < 0,001), total resection status (p < 0,001) and tumor localization
without SVZ contact (p = 0,05) were significant factors for prolonged survival.
Conclusion: Our findings underline that survival in GBM patients is heterogeneous and influenced by multiple
factors. This study confirms that tumor location with regard to the SVZ is significantly associated with survival.
Keywords: Glioblastoma, Subventricular zone, Long-term survival, Prognostic factorsIntroduction
Glioblastoma (GBM) are the most common primary brain
tumors in adults with poor survival rates of approximately
15 months after advanced chemoradiotherapy [1].
Even though multimodal therapy approaches improved,
prognosis changed little over the last decades [2]. Up to
date it is known that only about 2% of all GBM patients
survive longer than 36 months, a number that is likely to
increase in the near future due to therapeutic improve-
ments [3,4]. Interestingly individual patient survival is het-
erogeneous. The search to identify prognostic parameters* Correspondence: Sebastian.adeberg@med.uni-heidelberg.de
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unless otherwise stated.for shortened or prolonged survival is therefore currently
ongoing [5,6].
Numerous patient characteristics like age, gender, per-
formance status and tumor localization have been identi-
fied as potential prognostic factors [3,7]. Furthermore,
molecular markers like MGMT hypermethylation and
IDH1 mutation seem to play a growing role as predic-
tors for prognosis and therapeutic response in glioblast-
oma patients [8-10]. GBM LTS and STS have not been
studied in detail concerning tumor location in reference
to the SVZ. Recent studies demonstrated that the het-
erogeneity in patient survival and recurrence patterns of
patients with GBM may be related to neuronal stem
cells, located in the SVZ [10,11].
From a group of 909 patients, we selected LTS (> 36
months) and STS (< 12 months) to focus on outcome inal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Patient characteristics and results of short- and
long-term survivors with glioblastoma
Patient characteristics of STS and LTS
STS; n = 50 LTS; n = 5O
Age (years) 64, 8 51, 9
< 60 years 16 (32) 35 (60)
> 60 years 34 (68) 15 (30)
< 70 years 34 (68) 43 (86)
> 70 years 16 (32) 7 (14)
Male 33 (66) 26 (52)
Female 17 (34) 24 (48)
Tumor location
Right hemisphere 16 (32) 24 (48)
Left hemisphere 24 (48) 23 (46)
Both hemispheres 10 (20) 3 (6)
Location close to the ventricle (< 10 mm) 44 (88) 33 (68, 8)
Location distant to the ventricle (≥ 10 mm) 6 (12) 15 (31, 3)
Involvement of the ventricle system 30 (60) 18 (39, 1)
Multifocal disease 12 (24) 7 (15, 2)
Subependymal spread 15 (30) 5 (10, 9)
Extent of resection
Biopsy 26 (52) 5 (10, 4)
Total resection 7 (14) 22 (45,8)
Partial resection 17 (34) 22 (45,8)
Ventricle opening during surgery 8 (16) 17 (34,7)
Classification (Lim et al.)
Type I 18 (36) 21 (43,8)
Type II 16 (32) 6 (12, 5)
Type llI 9 (18) 15 (31, 3)
Type IV 7 (14) 6 (125)
MGMT hypermethyation 4 (36, 4) 12 (70, 6)
Radiotherapy within a study 23 (46) 25 (50)
GD (Gy) 56, 8 45, 1
RT as Re-irradiation 3 (6) 15 (30)
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100 patients were included into the present study, we
analyzed LTS and STS to validate prognostic factors for
patients diagnosed with GBM.
Patients and methods
Patient population
We identified 100 patients who matched our criteria of
LTS (survival over 36 months from the date of initial
diagnosis) or STS (survival under 12 months from the
date of initial diagnosis) with primary GBM [7,12-14].
We included 50 patients with LTS and 50 patients with
STS who have been treated with radiotherapy or chemo-
radiation between January 2004 and August 2013 at the
Department of Radiation Oncology/University Hospital
Heidelberg, Germany. Treatment decisions were made
according to the current treatment standard at the time,
respecting patient-individual factors such as age or per-
formance status. Patient characteristics of both groups
are shown in Table 1.
There were 33 (66%) male and 17 (34%) female patients
in the STS group with a median age of 64, 8 years (ranging
from 42, 5 to 77, 5 years) at the time of radiotherapy.
26 (52%) males and 24 (48%) females were included in the
LTS group with a mean age of 51, 9 years (ranging from
20, 3 to 73, 3 years). 23 (46%) STS and 25 (50%) LTS re-
ceived radiotherapy within a study.
We reviewed the clinical, hospital course records as
well as pre-operative and post-operative MRI imaging.
Data evaluation was performed according to institutional
guidelines.
Neuropathological diagnosis was determined accord-
ing to the most recent WHO classification system [15].
Patients were followed prospectively at the center ini-
tially 6 weeks after treatment and in 3 months intervals
in the following period until progress. No patient was lost
to follow-up which included contrast enhancing MRI
imaging. Preoperative images and follow-up examinations
until progress or death were assessed.Radiochemotherapy 35 (70) 38 (76)
Temozolomide 32 (64) 35 (70)
Numbers in brackets represent percentages and refer to the absolute values
in front.Radiotherapy/chemoradiotherapy
For treatment planning, patients were fixed with custom-
made mask fixation, computed tomography and MRI im-
aging were proceeded. A median dose of 60, 0 Gy (range
12, 0–68, 0 Gy) was delivered. Target volume definition
included the primary tumor region, including all contrast-
enhancing lesions (CEL) on T1-weighted MRI and the
T2-hyperintense region. A 2 to 3 cm safety margin for po-
tential microscopic spread was added.Imaging
All patients underwent preoperative MRI, treatment plan-
ning CT and postoperative follow up MRI available on theclinical intern picture archiving and communication sys-
tem (PACS).
Initial tumor localization and relapse localization were
determined based on T1 weighted sequences on axial and
coronal images. Images were assessed (T.W.) and reviewed
(T.B.) by experienced radiological specialists. The following
parameters were determined: localization of the primary
lesion, shortest distance of the CEL to the ventricle system
and subependymal spread. Multifocal disease was defined
as the presence of > 1 independent CEL noncontiguous to
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valued if the CEL contacted the lining of the ventricle. Ac-
cordingly tumors were classified as involving the cortex if
the CEL contacted the cortex. Tumors were considered
close to the ventricle if the shortest distance to a ventricle
was ≤ 10 mm and considered close to the ventricle if the
distance was > 10 mm. According to previously published
findings [10], LTS and STS were classified in 4 different
subtypes in reference to their location to the ventricle
system.
Statistical analysis
Analyses were performed using the software program
SigmaPlot™ (Systat Software GmbH, Germany). Survival
calculations were performed using Kaplan-Meier survival
curves. Prognostic factors were compared using the
Wilcoxon signed-rank test and the Mann–Whitney-U-
Test. Correlation of patient characteristics in subtypes
were determined using the Odds ratios, χ 2-test and cor-
responding 95% confidence intervals.
Results
Patient collective
We identified 50 STS and 50 LTS with primary GBM
who were treated with chemoradiotherapy/radiotherapy
over the 9 year study period. The median age of the STS
was significantly higher with 64, 8 years (range, 42, 5-77, 5
years) compared to 51, 9 years (ranging from 20, 3-73, 3
years) in LTS (p < 0,001). The gender distribution in STS
works with 2/3 in favor of the men (p = 0,22). In compari-
son the genders were spread almost evenly in the group of
LTS (m= 52%; f = 48%).
Treatment and pretreatments
A total of 24 STS (48%) underwent surgical resection as
initial treatment, which was complete in 7 cases (29, 2%)
and incomplete in 17 (70, 8%) cases. 26 patients (52%)
underwent biopsy only. 44 LTS were initially treated
with total (n = 22; 50%) or partial resection (n = 22; 50%).
Gross total tumor resection was performed more fre-
quent in LTS (OR: 5,002; 95% CI: 1,884 to 13,300; p <
0,001). In 5 cases (10, 4%) a biopsy was performed exclu-
sively. Resection status of one LTS was not determinable
with certainty. This patient was excluded in survival ana-
lysis with regards of resection status. In conclusion, STS
had a higher rate of biopsies for diagnosis confirmation
(OR = 9,533; 95% CI: 3,242 to 28,034, p < 0,001) and LTS
received surgery more often (OR: 5,005; 95% CI: 1,884
to 13,300, p = 0,002). There was no significant difference
of ventricle openings during surgery in STS (n = 8; 16%)
and LTS (n = 17; 34, 7%) (OR = 0,359; CI 95%: 0,138 to
0,934) (Table 1).
Concomitant chemotherapy with temozolomide (TMZ)
was applied to 32 (64%) STS and 38 LTS (76%). 3 (6%)STS and LTS each received combined therapy with a dif-
ferent agent (bevacizumab, cetuximab or temsirolimus).
No significant difference was observed between the LTS
and STS (OR = 0,737; 95% CI: 0,303 to 1,789).
3 (6%) STS and 15 (30%) LTS received radiotherapy as
a re-irradiation. Tumors of long-term survivors (n = 12,
70, 6%) had a higher occurrence frequency of hypermethy-
lated MGMT promoter status than in STS (n = 4; 36,4%).
Radiotherapy was performed as a re-irradiation in a sig-
nificantly higher percentage in LTS with 30% (n = 15) com-
pared to only 12% (n = 6) in STS (p = 0,05).
Tumor localization
STS had a higher frequency (n = 10; 20%) of prethera-
peutic bihemispheric tumor spread than LTS (n = 3; 6%)
(p = 0,074). Apart from that, the aspect ratio was distrib-
uted uniformly.
Significantly more STS (n = 44; 88%) showed a tumor
localization close to the ventricle system (≤ 10 mm) than
LTS (n = 33, 68, 8%) (OR = 3,333; 95% CI: 1,168 to 9,514;
p = 0,038). Accordingly more GBM in LTS (n = 15; 31, 3%)
were located distant (> 10 mm) to the closest ventricle
(p = 0,05). GBM of STS tended (p = 0,05) to infiltrate
the SVZ more frequent (n = 34; 68%) compared to LTS
(n = 27; 56, 3%). Conversely GBM of LTS were located
more likely (n = 21; 43, 8%) in the cortex area or white
matter not infiltrating the SVZ than STS (n = 16; 32%), as
shown in Figure 1 (OR = 2,789; 95% CI: 1,156 to 6,731).
In summary, ventricle involvement was more common
in STS (n = 30; 60%) compared to the LTS group (n = 18;
39, 1%) (p = 0,66). There was no significant correlation
between multifocal disease occurrence in both groups
(p = 0,308). 15 STS (30%) who were diagnosed with GBM
showed a subependymal tumor spread at the time of radio-
therapy in contrast to only 5 LTS (10, 9%) (OR = 3,514; CI:
95%: 1,160 to 10,643; p = 0,04).
Survival
Long-term survivors had a significantly higher PFS with
25, 4 months (range: 2, 3–97, 8 months) and OS with
55, 9 months (range: 38, 2-98, 6 months) than the con-
trol GBM patients, that we have published previously with
a PFS of 10, 4 months (±6, 7 months) and mean OS of
17, 7 months (±14, 8 months) (p < 0,001). Accordingly,
STS showed a significantly lower PFS of 4, 2 months
(range: 1, 4–10, 2 months) and OS of 6, 6 months (range:
2, 2–11, 6 months) than the control GBM group (p <
0,001) (Figure 2).
OS rates of LTS after complete resection with SVZ con-
tact were significantly higher than in STS after complete
resection with SVZ contact (86, 9 vs. 6, 3 months; p <
0,001). However LTS after partial resection with SVZ
involvement had a significantly decreased OS compared
to LTS after partial resection not involving the SVZ (41, 8
Figure 1 Glioblastoma on T1-weighted, post-contrast magnetic resonance images on the axial view. Tumor localization in the cortex
without subventricular zone involvement (left). Glioblastoma with infiltration of the subventricular zone and subependymal spread (right).
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complete tumor resection without SVZ contact did not
show a significant survival advantage compared to LTS
after complete resection with SVZ (48, 6 vs. 47, 1 months;
p = 0,5). Keeping in mind that in LTS following complete
tumor resection, 7 of 10 patients (70%) without SVZ con-
tact and 5 of 10 patients (50%) with SVZ contact were still
alive at the last follow up examination.
Discussion
Our study shows that long-term survival in GBM patients
is possible. It is known that only about 2, 2% of GBM
patients survive longer than 3 years after initial diagnosis
[3,16]. Preoperative clinical and radiological parameters
for survival remain understudied, even though few pre-
dictive values like performance status and age have beenFigure 2 Progression-free survival (left) and overall survival (right) of
of glioblastoma patients.determined in the past. Therefore we endeavored to
identify clinical parameters for prolonged and short-
ened survival. Our idea was to correlate patient charac-
teristics of both extremes, long-term survivors (OS > 36
months) on the one hand and short-term survivors (OS ≤
12 months) on the other.
The analysis of age distribution showed that LTS had a
significantly lower mean age (51, 9 years) than average
GBM patients (59, 5 years) as well as STS (64, 8 years)
(p < 0,001). This indicates that older age (> 60 years) is
associated with decreased survival and vice versa. Our
findings are consistent with previous published studies
[12,17,18]. However, 7 LTS were aged over 70 years, im-
plying that higher age per se does not exclude LTS and
this should be taken into account when defining treat-
ment algorithms for elderly patients.short-term survivors, long-term survivors and a reference group
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4-1, 6 of male to female patients [19]. In our collective
of LTS, the ratio was 1,1 and 1,9 in STS. These findings
indicate that females are overrepresented in LTS and
males in STS. Hence no statistical significance could be
observed. Krex et al. also described a higher proportion
of females, with a male/female ratio of 1,04 in their LTS-
collective of 55 patients showing that female gender seems
to be favorable for increased survival [12].
Besides basic patient characteristics, recent researches
have shown that tumor localization in reference to the
SVZ and potential stem-like glioblastoma cells is a predict-
ive factor for survival [7] (*). Interestingly our data showed
a higher rate of glioblastoma localization in cortical areas
or white marrow without SVZ contact (p = 0,05) and dis-
tant (> 10 mm) to the ventricle system (p = 0,038). On the
other hand, STS showed higher frequency of GBM loca-
tion close (≤ 10 mm) to the ventricle system (p = 0,05), a
higher incidence of SVZ involvement (p = 0,05) and sub-
ependymal spread (p = 0,066). These findings corres-
pond with reports in the literature [10,11] (*) where tumor
localization close to the SVZ or ventricle system was con-
nected with decreased survival. Parsa et al. described
an increased survival rate of GBM patients with sube-
pendymal tumor spread in a collective of patients with dis-
seminated GBM disease [20]. Chaichana et al. [7] found a
negative prognostic association between periventricular
tumor localization and survival. The main reasons for a
less favorable outcome in GBM patients with SVZ involve-
ment are not yet completely understood. Experiments and
clinical findings provide evidence that neuronal progenitor
cells in the SVZ with a high migratory potential are in-
volved in an aggressive glioblastoma subtype [21]. Another
possibility is the close proximity of GBM with ventricle as-
sociation to a higher density of subcortical fibers and crit-
ical neurological tissue than peripheral tumors [22].
Furthermore, surgical resection status during initial treat-
ment is an established predictive factor for survival in GBM
patients. Total resection is presumed to be associated with
a favorable prognosis [3,12,23]. In our collective of LTS, a
higher rate of completely resected patients at the time of
initial treatment could be observed (p = 0,002). In contrast
a higher rate of STS were diagnosed by biopsy previous to
the primary radio- or radio-/chemotherapy (p < 0,001), con-
cluding that complete resection status is prognostic for
improved survival in patients with GBM.
There was no significant difference between the ratio
of LTS and STS receiving a concomitant chemoradio-
therapy with temozolomide. Overall the fraction receiving
a combined therapy was high in both groups, with about
70%. Temozolomide-based bimodal therapy is known to
increase survival rates in glioblastoma patients [1].
Our study has several limitations due to its retrospect-
ive design. This cohort was not consecutively treated.Furthermore patient’s performance status (Karnofsky index),
was not documented consistently and could not be evalu-
ated. Poor performance status is known to correlate with
worse OS and may lead to major bias for our survival ana-
lysis. Resection status as an important covariate may con-
found our survival analysis with regard to the SVZ, taking
into account that LTS had a higher frequency of total re-
sections (22 vs. 7 patients).
Moreover numerous patients with malignant glioma
are included in study trials in our department, to evalu-
ate new clinical approaches. In this study, the propor-
tion of GBM patients being treated within a study trial
was almost equal in LTS and STS with about 50% each,
concluding that treatment in study setups in our de-
partment is non-inferior to our standard treatment
protocols.
Despite clinical characteristics, molecular markers play
a growing role in determining therapeutic response and
prognosis in GBM patients [13,14]. Our data show a
higher rate of MGMT hypermethylated promotors in
GBM LTS than in STS. The patient groups were too
small to achieve a significant pronunciation (p = 0,121).
These findings support the clinical results implicating
MGMT promoter methylation as a positive predictor
for therapeutic response to temozolomide and increased
survival [8]. It is important to add that neither lack-
ing MGMT-hypermethylation precludes long-term survival
nor MGMT-hypermethylation prevents a patient from be-
coming a STS.
Conclusions
This study underlines that survival in GBM patients is
heterogeneous and influenced by multiple factors. We
found a correlation between long-term survival and young
age, total resection status, no SVZ contact and localization
distant to the ventricle system.
On the other hand, these data suggest an association
between short-term survival and higher age, no resec-
tion, SVZ involvement, localization close to the ventricle
system and subependymal tumor spread.
These prognostic indicators serve to identify high risk
groups that should be treated at an early course of the
disease with an aggressive regime. Furthermore these find-
ings help to estimate prognosis, define treatment volume
in radiotherapy and serve as a foundation for future inves-
tigations on LTS and STS.
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